<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'><collection><source>PubTator</source><date></date><key>BioC.key</key><document><id>31106894</id><passage><infon key="journal">Microbiol. Immunol.; 2019 May 201 doi:10.1111/1348-0421.12688</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Domon H, Hiyoshi T, Maekawa T, Yonezawa D, Tamura H, Kawabata S, Yanagihara K, Kimura O, Kunitomo E, Terao Y, </infon><offset>0</offset><text>Antibacterial activity of hinokitiol against both antibiotic-resistant and -susceptible pathogenic bacteria predominant in the oral cavity and upper airways.</text><annotation id="2"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="26"/><text>hinokitiol</text></annotation><annotation id="3"><infon key="identifier">2</infon><infon key="type">Species</infon><location length="8" offset="99"/><text>bacteria</text></annotation></passage><passage><infon key="type">abstract</infon><offset>158</offset><text>Hinokitiol is a component of the essential oil isolated from Cupressaceae. It possesses antibacterial and antifungal activities and has been used in oral care products. In this study, we examined the antibacterial activities of hinokitiol toward various oral, nasal, and nasopharyngeal pathogenic bacteria, including Streptococcus mutans, Streptococcus sobrinus, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, Prevotella intermedia, Fusobacterium nucleatum, methicillin-resistant and -susceptible Staphylococcus aureus, antibiotic-resistant and -susceptible Streptococcus pneumoniae, and Streptococcus pyogenes. The growth of all bacterial strains was significantly inhibited by hinokitiol. The minimal inhibitory concentrations of hinokitiol against S. mutans, S. sobrinus, P. gingivalis, P. intermedia, A. actinomycetemcomitans, F. nucleatum, methicillin-resistant S. aureus, methicillin-susceptible S. aureus, antibiotic-resistant S. pneumoniae isolates, antibiotic-susceptible S. pneumoniae, and S. pyogenes were 0.3, 1.0, 1.0, 30, 0.5, 50, 50, 30, 0.3-1.0, 0.5, and 0.3 mug/mL, respectively. Additionally, with the exception of P. gingivalis, hinokitiol exerted bactericidal effects against all bacterial strains at 1 h after exposure. Hinokitiol did not display any significant cytotoxicity toward the human gingival epithelial cell line Ca9-22, pharyngeal epithelial cell line Detroit 562, human umbilical vein endothelial cells, and human gingival fibroblasts, with the exception of 500 mug/mL hinokitiol treatment, which decreased viable Ca9-22 cells and gingival fibroblasts by 13% and 12%, respectively. These results suggest that hinokitiol exhibits antibacterial activity against a broad spectrum of pathogenic bacteria and low cytotoxicity towards human epithelial cells. This article is protected by copyright. All rights reserved.</text><annotation id="44"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="158"/><text>Hinokitiol</text></annotation><annotation id="45"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="386"/><text>hinokitiol</text></annotation><annotation id="46"><infon key="identifier">2</infon><infon key="type">Species</infon><location length="8" offset="455"/><text>bacteria</text></annotation><annotation id="47"><infon key="identifier">1309</infon><infon key="type">Species</infon><location length="20" offset="475"/><text>Streptococcus mutans</text></annotation><annotation id="48"><infon key="identifier">1310</infon><infon key="type">Species</infon><location length="22" offset="497"/><text>Streptococcus sobrinus</text></annotation><annotation id="49"><infon key="identifier">837</infon><infon key="type">Species</infon><location length="24" offset="521"/><text>Porphyromonas gingivalis</text></annotation><annotation id="50"><infon key="identifier">714</infon><infon key="type">Species</infon><location length="37" offset="547"/><text>Aggregatibacter actinomycetemcomitans</text></annotation><annotation id="51"><infon key="identifier">28131</infon><infon key="type">Species</infon><location length="21" offset="586"/><text>Prevotella intermedia</text></annotation><annotation id="52"><infon key="identifier">851</infon><infon key="type">Species</infon><location length="23" offset="609"/><text>Fusobacterium nucleatum</text></annotation><annotation id="53"><infon key="Identifier">MESH:D008712</infon><infon key="type">Chemical</infon><location length="11" offset="634"/><text>methicillin</text></annotation><annotation id="54"><infon key="identifier">1313</infon><infon key="type">Species</infon><location length="24" offset="734"/><text>Streptococcus pneumoniae</text></annotation><annotation id="55"><infon key="identifier">1314</infon><infon key="type">Species</infon><location length="22" offset="764"/><text>Streptococcus pyogenes</text></annotation><annotation id="56"><infon key="identifier">2</infon><infon key="type">Species</infon><location length="9" offset="806"/><text>bacterial</text></annotation><annotation id="57"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="855"/><text>hinokitiol</text></annotation><annotation id="58"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="908"/><text>hinokitiol</text></annotation><annotation id="59"><infon key="identifier">1309</infon><infon key="type">Species</infon><location length="9" offset="927"/><text>S. mutans</text></annotation><annotation id="60"><infon key="identifier">1310</infon><infon key="type">Species</infon><location length="11" offset="938"/><text>S. sobrinus</text></annotation><annotation id="61"><infon key="identifier">837</infon><infon key="type">Species</infon><location length="13" offset="951"/><text>P. gingivalis</text></annotation><annotation id="62"><infon key="identifier">28131</infon><infon key="type">Species</infon><location length="13" offset="966"/><text>P. intermedia</text></annotation><annotation id="63"><infon key="identifier">851</infon><infon key="type">Species</infon><location length="12" offset="1007"/><text>F. nucleatum</text></annotation><annotation id="64"><infon key="Identifier">MESH:D008712</infon><infon key="type">Chemical</infon><location length="11" offset="1021"/><text>methicillin</text></annotation><annotation id="65"><infon key="identifier">1280</infon><infon key="type">Species</infon><location length="9" offset="1043"/><text>S. aureus</text></annotation><annotation id="66"><infon key="Identifier">MESH:D008712</infon><infon key="type">Chemical</infon><location length="11" offset="1054"/><text>methicillin</text></annotation><annotation id="67"><infon key="identifier">2104</infon><infon key="type">Species</infon><location length="13" offset="1157"/><text>S. pneumoniae</text></annotation><annotation id="68"><infon key="identifier">1314</infon><infon key="type">Species</infon><location length="11" offset="1176"/><text>S. pyogenes</text></annotation><annotation id="69"><infon key="identifier">837</infon><infon key="type">Species</infon><location length="13" offset="1309"/><text>P. gingivalis</text></annotation><annotation id="70"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="1324"/><text>hinokitiol</text></annotation><annotation id="71"><infon key="identifier">2</infon><infon key="type">Species</infon><location length="9" offset="1376"/><text>bacterial</text></annotation><annotation id="72"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="1417"/><text>Hinokitiol</text></annotation><annotation id="73"><infon key="Identifier">MESH:D064420</infon><infon key="type">Disease</infon><location length="12" offset="1460"/><text>cytotoxicity</text></annotation><annotation id="74"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="5" offset="1484"/><text>human</text></annotation><annotation id="75"><infon key="Identifier">CVCL:1102</infon><infon key="type">CellLine</infon><location length="6" offset="1520"/><text>Ca9-22</text></annotation><annotation id="76"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="5" offset="1573"/><text>human</text></annotation><annotation id="77"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="5" offset="1617"/><text>human</text></annotation><annotation id="78"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="1678"/><text>hinokitiol</text></annotation><annotation id="79"><infon key="Identifier">CVCL:1102</infon><infon key="type">CellLine</infon><location length="6" offset="1723"/><text>Ca9-22</text></annotation><annotation id="80"><infon key="Identifier">MESH:C009479</infon><infon key="type">Chemical</infon><location length="10" offset="1818"/><text>hinokitiol</text></annotation><annotation id="81"><infon key="identifier">2</infon><infon key="type">Species</infon><location length="8" offset="1900"/><text>bacteria</text></annotation><annotation id="82"><infon key="Identifier">MESH:D009800</infon><infon key="type">Disease</infon><location length="16" offset="1913"/><text>low cytotoxicity</text></annotation><annotation id="83"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="5" offset="1938"/><text>human</text></annotation></passage></document><document><id>31107214</id><passage><infon key="journal">Emerging Infect. Dis.; 2019 Jun1 2516) 1218-1219. doi:10.3201/eid2506.171431</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Qin T, Ren H, Chen D, Zhou H, Jiang L, Wu D, Shen J, Pei F, </infon><offset>0</offset><text>National Surveillance of Legionnaires' Disease, China, 2014-2016.</text><annotation id="1"><infon key="Identifier">MESH:D007877</infon><infon key="type">Disease</infon><location length="21" offset="25"/><text>Legionnaires' Disease</text></annotation></passage><passage><infon key="type">abstract</infon><offset>66</offset><text>We report national surveillance of Legionnaires' disease in China. Urine samples from 11 (3.85%) of 286 patients with severe pneumonia of unknown cause were positive for the Legionella pneumophila serogroup 1 antigen. We isolated Legionella strains from 7 patients. Improved diagnostic testing is needed for this underestimated disease in China.</text><annotation id="6"><infon key="Identifier">MESH:D007877</infon><infon key="type">Disease</infon><location length="21" offset="101"/><text>Legionnaires' disease</text></annotation><annotation id="7"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="170"/><text>patients</text></annotation><annotation id="8"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="191"/><text>pneumonia</text></annotation><annotation id="9"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="322"/><text>patients</text></annotation></passage></document><document><id>31107230</id><passage><infon key="journal">Emerging Infect. Dis.; 2019 Jun1 2516) 1127-1135. doi:10.3201/eid2506.180532</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Yu J, Liu C, Xiao Y, Xiang Z, Zhou H, Chen L, Shen K, Xie Z, Ren L, Wang J, </infon><offset>0</offset><text>Respiratory Syncytial Virus Seasonality, Beijing, China, 2007-2015.</text><annotation id="1"><infon key="identifier">12814</infon><infon key="type">Species</infon><location length="27" offset="0"/><text>Respiratory Syncytial Virus</text></annotation></passage><passage><infon key="type">abstract</infon><offset>68</offset><text>During July 2007-June 2015, we enrolled 4,225 hospitalized children with pneumonia in a study to determine the seasonality of respiratory syncytial virus (RSV) infection in Beijing, China. We defined season as the period during which &amp;gt;10% of total PCRs performed each week were RSV positive. We identified 8 distinctive RSV seasons. On average, the season onset occurred at week 41 (mid-October) and lasted 33 weeks, through week 20 of the next year (mid-May); 97% of all RSV-positive cases occurred during the season. RSV seasons occurred 3-5 weeks earlier and lasted  6 weeks longer in RSV subgroup A-dominant years than in RSV subgroup B-dominant years. Our analysis indicates that monitoring such RSV subgroup shifts might provide better estimates for the onset of RSV transmission. PCR-based tests could be a flexible or complementary way of determining RSV seasonality in locations where RSV surveillance is less well-established, such as local hospitals throughout China.</text><annotation id="15"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="127"/><text>children</text></annotation><annotation id="16"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="141"/><text>pneumonia</text></annotation><annotation id="17"><infon key="Identifier">MESH:D018357</infon><infon key="type">Disease</infon><location length="58" offset="179"/><text>seasonality of respiratory syncytial virus (RSV) infection</text></annotation><annotation id="18"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="349"/><text>RSV</text></annotation><annotation id="19"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="391"/><text>RSV</text></annotation><annotation id="20"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="543"/><text>RSV</text></annotation><annotation id="21"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="590"/><text>RSV</text></annotation><annotation id="22"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="659"/><text>RSV</text></annotation><annotation id="23"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="697"/><text>RSV</text></annotation><annotation id="24"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="772"/><text>RSV</text></annotation><annotation id="25"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="840"/><text>RSV</text></annotation><annotation id="26"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="930"/><text>RSV</text></annotation><annotation id="27"><infon key="identifier">11886</infon><infon key="type">Species</infon><location length="3" offset="965"/><text>RSV</text></annotation></passage></document><document><id>31107250</id><passage><infon key="journal">Curr. Opin. Infect. Dis.; 2019 May 161 doi:10.1097/QCO.0000000000000559</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Guegan H, Robert-Gangneux F, </infon><offset>0</offset><text>Molecular diagnosis of Pneumocystis pneumonia in immunocompromised patients.</text><annotation id="2"><infon key="Identifier">MESH:D011020</infon><infon key="type">Disease</infon><location length="22" offset="23"/><text>Pneumocystis pneumonia</text></annotation><annotation id="3"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="67"/><text>patients</text></annotation></passage><passage><infon key="type">abstract</infon><offset>77</offset><text>PURPOSE OF REVIEW: Pneumocystis pneumonia (PCP) is a frequent opportunistic infection associated with a high mortality rate. PCP is of increasing importance in non-HIV immunocompromised patients, who present with severe respiratory distress with low fungal loads. Molecular detection of Pneumocystis in broncho-alveolar lavage (BAL) has become an important diagnostic tool, but quantitative PCR (qPCR) needs standardization. RECENT FINDINGS: Despite a high negative predictive value, the positive predictive value of qPCR is moderate, as it also detects colonized patients. Attempts are made to set a cut-off value of qPCR to discriminate between PCP and colonization, or to use noninvasive samples or combined strategies to increase specificity. SUMMARY: It is easy to set a qPCR cut-off for HIV-infected patients. In non-HIV IC patients, a gain in specificity could be obtained by combining strategies, that is, qPCR on BAL and a noninvasive sample, or qPCR and serum beta-1,3-D-glucan dosage.</text><annotation id="19"><infon key="Identifier">MESH:D011020</infon><infon key="type">Disease</infon><location length="22" offset="96"/><text>Pneumocystis pneumonia</text></annotation><annotation id="20"><infon key="Identifier">MESH:D011020</infon><infon key="type">Disease</infon><location length="3" offset="120"/><text>PCP</text></annotation><annotation id="21"><infon key="Identifier">MESH:D009894</infon><infon key="type">Disease</infon><location length="23" offset="139"/><text>opportunistic infection</text></annotation><annotation id="22"><infon key="Identifier">MESH:D011020</infon><infon key="type">Disease</infon><location length="3" offset="202"/><text>PCP</text></annotation><annotation id="23"><infon key="identifier">11709</infon><infon key="type">Species</infon><location length="3" offset="241"/><text>HIV</text></annotation><annotation id="24"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="263"/><text>patients</text></annotation><annotation id="25"><infon key="Identifier">MESH:D012128</infon><infon key="type">Disease</infon><location length="20" offset="297"/><text>respiratory distress</text></annotation><annotation id="26"><infon key="identifier">4751</infon><infon key="type">Species</infon><location length="6" offset="327"/><text>fungal</text></annotation><annotation id="27"><infon key="Identifier">MESH:D016720</infon><infon key="type">Disease</infon><location length="12" offset="364"/><text>Pneumocystis</text></annotation><annotation id="28"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="641"/><text>patients</text></annotation><annotation id="29"><infon key="Identifier">MESH:D011020</infon><infon key="type">Disease</infon><location length="3" offset="724"/><text>PCP</text></annotation><annotation id="30"><infon key="Identifier">MESH:D015658</infon><infon key="type">Disease</infon><location length="12" offset="870"/><text>HIV-infected</text></annotation><annotation id="31"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="883"/><text>patients</text></annotation><annotation id="32"><infon key="identifier">11709</infon><infon key="type">Species</infon><location length="3" offset="900"/><text>HIV</text></annotation><annotation id="33"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="907"/><text>patients</text></annotation></passage></document><document><id>31107274</id><passage><infon key="journal">Anesthesiology; 2019 May 151 doi:10.1097/ALN.0000000000002752</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Dhanani JA, Diab S, Chaudhary J, Cohen J, Parker SL, Wallis SC, Boidin C, Barnett A, Chew M, Roberts JA, Fraser JF, </infon><offset>0</offset><text>Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model.</text><annotation id="1"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="25"/><text>Tobramycin</text></annotation></passage><passage><infon key="type">abstract</infon><offset>122</offset><text>WHAT WE ALREADY KNOW ABOUT THIS TOPIC: For most bacterial pneumonia, the lung interstitium is considered to be the site of infection, and adequate antibiotic concentrations are important for drug effectDespite systemic antibiotic therapy, therapeutic failure is common, perhaps due to poor lung penetration, and resulting low interstitial space fluid antibiotic concentrationsIncreasing systemic antibiotic doses in order to increase interstitial space fluid antibiotic concentrations could lead to toxicities such as nephrotoxicity WHAT THIS ARTICLE TELLS US THAT IS NEW: In a mechanically ventilated healthy large animal model, nebulized tobramycin produced higher peak lung interstitial space fluid concentrations, as well as higher initial epithelial lining fluid concentrations, with lower plasma concentrations than were observed after intravenous administration due to more extensive lung penetration BACKGROUND:: Nebulized antibiotics may be used to treat ventilator-associated pneumonia. In previous pharmacokinetic studies, lung interstitial space fluid concentrations have never been reported. The aim of the study was to compare intravenous and nebulized tobramycin concentrations in the lung interstitial space fluid, epithelial lining fluid, and plasma in mechanically ventilated sheep with healthy lungs. METHODS: Ten anesthetized and mechanically ventilated healthy ewes underwent surgical insertion of microdialysis catheters in upper and lower lobes of both lungs and the jugular vein. Five ewes were given intravenous tobramycin 400 mg, and five were given nebulized tobramycin 400 mg. Microdialysis samples were collected every 20 min for 8 h. Bronchoalveolar lavage was performed at 1 and 6 h. RESULTS: The peak lung interstitial space fluid concentrations were lower with intravenous tobramycin 20.2 mg/l (interquartile range, 12 mg/l, 26.2 mg/l) versus the nebulized route 48.3 mg/l (interquartile range, 8.7 mg/l, 513 mg/l), P = 0.002. For nebulized tobramycin, the median epithelial lining fluid concentrations were higher than the interstitial space fluid concentrations at 1 h (1,637; interquartile range, 650, 1,781, vs. 16 mg/l, interquartile range, 7, 86, P &amp;lt; 0.001) and 6 h (48, interquartile range, 17, 93, vs. 4 mg/l, interquartile range, 2, 9, P &amp;lt; 0.001). For intravenous tobramycin, the median epithelial lining fluid concentrations were lower than the interstitial space fluid concentrations at 1 h (0.19, interquartile range, 0.11, 0.31, vs. 18.5 mg/l, interquartile range, 9.8, 23.4, P &amp;lt; 0.001) and 6 h (0.34, interquartile range, 0.2, 0.48, vs. 3.2 mg/l, interquartile range, 0.9, 4.4, P &amp;lt; 0.001). CONCLUSIONS: Compared with intravenous tobramycin, nebulized tobramycin achieved higher lung interstitial fluid and epithelial lining fluid concentrations without increasing systemic concentrations.</text><annotation id="18"><infon key="Identifier">MESH:D018410</infon><infon key="type">Disease</infon><location length="19" offset="170"/><text>bacterial pneumonia</text></annotation><annotation id="19"><infon key="Identifier">MESH:D007239</infon><infon key="type">Disease</infon><location length="9" offset="245"/><text>infection</text></annotation><annotation id="20"><infon key="Identifier">MESH:D017093</infon><infon key="type">Disease</infon><location length="7" offset="373"/><text>failure</text></annotation><annotation id="21"><infon key="Identifier">MESH:D064420</infon><infon key="type">Disease</infon><location length="10" offset="621"/><text>toxicities</text></annotation><annotation id="22"><infon key="Identifier">MESH:D007674</infon><infon key="type">Disease</infon><location length="14" offset="640"/><text>nephrotoxicity</text></annotation><annotation id="23"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="762"/><text>tobramycin</text></annotation><annotation id="24"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="1108"/><text>pneumonia</text></annotation><annotation id="25"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="1289"/><text>tobramycin</text></annotation><annotation id="26"><infon key="identifier">9940</infon><infon key="type">Species</infon><location length="5" offset="1416"/><text>sheep</text></annotation><annotation id="27"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="1659"/><text>tobramycin</text></annotation><annotation id="28"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="1708"/><text>tobramycin</text></annotation><annotation id="29"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="1928"/><text>tobramycin</text></annotation><annotation id="30"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="2096"/><text>tobramycin</text></annotation><annotation id="31"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="2434"/><text>tobramycin</text></annotation><annotation id="32"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="2810"/><text>tobramycin</text></annotation><annotation id="33"><infon key="Identifier">MESH:D014031</infon><infon key="type">Chemical</infon><location length="10" offset="2832"/><text>tobramycin</text></annotation></passage></document><document><id>31107351</id><passage><infon key="journal">Eur J Anaesthesiol; 2019 May 151 doi:10.1097/EJA.0000000000001022</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Dureau P, Bouglé A, Melac AT, Ait Hamou N, Arbelot C, Ben Hassen K, Charfeddine A, Deransy R, Arcile G, Rouby JJ, Granger B, Amour J, </infon><offset>0</offset><text>Colour Doppler ultrasound after major cardiac surgery improves diagnostic accuracy of the pulmonary infection score in acute respiratory failure: A prospective observational study.</text><annotation id="2"><infon key="Identifier">MESH:D011655</infon><infon key="type">Disease</infon><location length="19" offset="90"/><text>pulmonary infection</text></annotation><annotation id="3"><infon key="Identifier">MESH:D012131</infon><infon key="type">Disease</infon><location length="25" offset="119"/><text>acute respiratory failure</text></annotation></passage><passage><infon key="type">abstract</infon><offset>181</offset><text>BACKGROUND: Postoperative pneumonia is a frequent complication after cardiac surgery, and its diagnosis is difficult. Little is known about the diagnostic accuracy of lung ultrasound (LUS) in the detection of pneumonia in cardiac surgical patients. The substitution of chest radiography by colour Doppler LUS (LUS-sCPIS) in the simplified clinical pulmonary infection score (sCPIS) could improve the diagnosis of pneumonia following cardiac surgery. OBJECTIVE: The aim of this study was to compare the diagnostic accuracy of LUS-sCPIS and of sCPIS alone in the detection of postoperative pneumonia after cardiac surgery. DESIGN: A prospective study of diagnostic accuracy. SETTING: A Surgical Intensive Care Unit of a French University Hospital. PATIENTS: Fifty-one patients with acute respiratory failure within 72 h after cardiac surgery were enrolled between January and May 2015. MAIN OUTCOME MEASURE: The two index tests, LUS-sCPIS and sCPIS, were calculated for all patients at the onset of acute respiratory failure. The reference standard for the diagnosis of pneumonia was based on the consensus of three physicians, blind to the sCPIS and LUS-sCPIS data, based on a posthoc review of all the clinical, radiological and microbiological evidence. The diagnostic accuracy of LUS-sCPIS was compared with that of sCPIS in the detection of postoperative pneumonia. RESULTS: Pneumonia was diagnosed in 26 out of 51 patients. The LUS-sCPIS detected the presence of pneumonia with a sensitivity of 92% (95% CI 0.85 to 0.99) and a specificity of 68% (95% CI 0.55 to 0.81). The sCPIS detected the presence of pneumonia with a sensitivity of 35% (95% CI 0.22 to 0.48) and a specificity of 84% (95% CI 0.74 to 0.94). The area under the curve (AUC) of LUS-sCPIS at 0.80 (95% CI 0.69 to 0.91) was higher than the AUC of sCPIS at 0.59 (95% CI 0.47 to 0.71; P = 0.0008). CONCLUSION: Compared with sCPIS, LUS-sCPIS improved diagnostic accuracy in the detection of postoperative pneumonia in patients with acute respiratory failure after cardiac surgery. It could be a useful bedside tool to guide pneumonia management. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT03279887.</text><annotation id="24"><infon key="Identifier">MESH:D010149</infon><infon key="type">Disease</infon><location length="23" offset="193"/><text>Postoperative pneumonia</text></annotation><annotation id="25"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="390"/><text>pneumonia</text></annotation><annotation id="26"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="420"/><text>patients</text></annotation><annotation id="27"><infon key="Identifier">MESH:D011655</infon><infon key="type">Disease</infon><location length="19" offset="529"/><text>pulmonary infection</text></annotation><annotation id="28"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="594"/><text>pneumonia</text></annotation><annotation id="29"><infon key="Identifier">MESH:D010149</infon><infon key="type">Disease</infon><location length="23" offset="755"/><text>postoperative pneumonia</text></annotation><annotation id="30"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="927"/><text>PATIENTS</text></annotation><annotation id="31"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="947"/><text>patients</text></annotation><annotation id="32"><infon key="Identifier">MESH:D012131</infon><infon key="type">Disease</infon><location length="25" offset="961"/><text>acute respiratory failure</text></annotation><annotation id="33"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="1153"/><text>patients</text></annotation><annotation id="34"><infon key="Identifier">MESH:D012131</infon><infon key="type">Disease</infon><location length="25" offset="1178"/><text>acute respiratory failure</text></annotation><annotation id="35"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="1249"/><text>pneumonia</text></annotation><annotation id="36"><infon key="Identifier">MESH:D010149</infon><infon key="type">Disease</infon><location length="23" offset="1525"/><text>postoperative pneumonia</text></annotation><annotation id="37"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="1599"/><text>patients</text></annotation><annotation id="38"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="1648"/><text>pneumonia</text></annotation><annotation id="39"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="1789"/><text>pneumonia</text></annotation><annotation id="40"><infon key="Identifier">MESH:D010149</infon><infon key="type">Disease</infon><location length="23" offset="2137"/><text>postoperative pneumonia</text></annotation><annotation id="41"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="2164"/><text>patients</text></annotation><annotation id="42"><infon key="Identifier">MESH:D012131</infon><infon key="type">Disease</infon><location length="25" offset="2178"/><text>acute respiratory failure</text></annotation><annotation id="43"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="2270"/><text>pneumonia</text></annotation></passage></document><document><id>31107422</id><passage><infon key="journal">Pediatr. Infect. Dis. J.; 2019 May 151 doi:10.1097/INF.0000000000002383</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Vallejo JG, McNeil JC, Hultén KG, Sommer LM, Dunn JJ, Kaplan SL, </infon><offset>0</offset><text>Invasive Haemophilus influenzae Disease at Texas Children's Hospital, 2011 to 2018.</text><annotation id="2"><infon key="Identifier">MESH:D008583</infon><infon key="type">Disease</infon><location length="30" offset="9"/><text>Haemophilus influenzae Disease</text></annotation><annotation id="3"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="49"/><text>Children</text></annotation></passage><passage><infon key="type">abstract</infon><offset>84</offset><text>BACKGROUND: Universal vaccination with Haemophilus influenzae type b conjugate vaccines has significantly changed the epidemiology of invasive H. influenzae disease in the United States. We reviewed the epidemiology, clinical features, and outcomes in 61 patients with invasive H. influenzae disease evaluated at Texas Children's Hospital (TCH). METHODS: Cases of invasive H. influenzae disease, defined as isolation of the organism from cerebrospinal fluid, blood, synovial fluid or pleural fluid, during 2011 to 2018 among children cared for at TCH in Houston, TX, were included. RESULTS: We identified 61 cases of invasive H. influenzae disease in children &amp;lt;=18 years of age. The overall hospitalization rate due to invasive H. influenzae disease increased between 2011 and 2018 (0 vs. 0.64/1000 hospitalizations; P = 0.019). The majority (80%) of infections occurred in children &amp;lt;5 years of age. Of the 61 H. influenzae infections, 24 (39.3%) infections were caused by nontypeable H. influenzae strains, 18 (29.5%) infections were caused by H. influenzae type a, 12 (19.7%) infections were caused by H. influenzae type f, 3 (4.9%) infections were caused by H. influenzae type e and 4 (6.6%) isolates were not typed. A total of 78.7% of the isolates were beta-lactamase negative. The most common clinical presentations were bacteremia without a source, pneumonia and meningitis. CONCLUSIONS: The hospitalization rate for H. influenzae invasive disease increased over an 8-year period at TCH. The overall trend was mainly driven by an increasing number of invasive infections caused by nontypeable H. influenzae and H. influenzae type a. Morbidity was substantial, especially in meningitis cases.</text><annotation id="28"><infon key="Identifier">MESH:D008583</infon><infon key="type">Disease</infon><location length="29" offset="123"/><text>Haemophilus influenzae type b</text></annotation><annotation id="29"><infon key="Identifier">MESH:D007251</infon><infon key="type">Disease</infon><location length="30" offset="218"/><text>invasive H. influenzae disease</text></annotation><annotation id="30"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="339"/><text>patients</text></annotation><annotation id="31"><infon key="Identifier">MESH:D007251</infon><infon key="type">Disease</infon><location length="30" offset="353"/><text>invasive H. influenzae disease</text></annotation><annotation id="32"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="403"/><text>Children</text></annotation><annotation id="33"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="457"/><text>H. influenzae</text></annotation><annotation id="34"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="609"/><text>children</text></annotation><annotation id="35"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="710"/><text>H. influenzae</text></annotation><annotation id="36"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="735"/><text>children</text></annotation><annotation id="37"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="815"/><text>H. influenzae</text></annotation><annotation id="38"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="961"/><text>children</text></annotation><annotation id="39"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1000"/><text>H. influenzae</text></annotation><annotation id="40"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1075"/><text>H. influenzae</text></annotation><annotation id="41"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1135"/><text>H. influenzae</text></annotation><annotation id="42"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1194"/><text>H. influenzae</text></annotation><annotation id="43"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1251"/><text>H. influenzae</text></annotation><annotation id="44"><infon key="Identifier">MESH:D016470</infon><infon key="type">Disease</infon><location length="10" offset="1417"/><text>bacteremia</text></annotation><annotation id="45"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="24" offset="1446"/><text>pneumonia and meningitis</text></annotation><annotation id="46"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1514"/><text>H. influenzae</text></annotation><annotation id="47"><infon key="Identifier">MESH:D009361</infon><infon key="type">Disease</infon><location length="16" offset="1528"/><text>invasive disease</text></annotation><annotation id="48"><infon key="Identifier">MESH:D009361</infon><infon key="type">Disease</infon><location length="19" offset="1648"/><text>invasive infections</text></annotation><annotation id="49"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1690"/><text>H. influenzae</text></annotation><annotation id="50"><infon key="identifier">727</infon><infon key="type">Species</infon><location length="13" offset="1708"/><text>H. influenzae</text></annotation><annotation id="51"><infon key="Identifier">MESH:D008581</infon><infon key="type">Disease</infon><location length="10" offset="1771"/><text>meningitis</text></annotation></passage></document><document><id>31107533</id><passage><infon key="journal">J Pediatric Infect Dis Soc; 2019 May 201 doi:10.1093/jpids/piz026</infon><infon key="year">2019</infon><infon key="type">title</infon><infon key="authors">Florin TA, Byczkowski T, Gerber JS, Ruddy R, Kuppermann N, </infon><offset>0</offset><text>Diagnostic Testing and Antibiotic Use in Young Children With Community-Acquired Pneumonia in the United States, 2008-2015.</text><annotation id="1"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="47"/><text>Children</text></annotation></passage><passage><infon key="type">abstract</infon><offset>123</offset><text>Diagnostic testing and antibiotics are not routinely recommended for young children with community-acquired pneumonia. In a national sample of &amp;gt;6 million outpatient 1- to 6-year-olds with community-acquired pneumonia between 2008 and 2015, a complete blood count was obtained for 8.6% (95% confidence interval [CI], 6.1%-11.1%), radiography was performed for 43% (95% CI, 36%-50%), and antibiotics were given for 73.9% (95% CI, 67.1%-80.7%). There were no changes in testing or antibiotic use over time.</text><annotation id="5"><infon key="identifier">9606</infon><infon key="type">Species</infon><location length="8" offset="198"/><text>children</text></annotation><annotation id="6"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="231"/><text>pneumonia</text></annotation><annotation id="7"><infon key="Identifier">MESH:D011014</infon><infon key="type">Disease</infon><location length="9" offset="333"/><text>pneumonia</text></annotation></passage></document></collection>
